Výsledky vyhledávání

Immuntherapie bei Kopf-Hals-Plattenepithelkarzinomen

Autor: Lara Dunn, Kirsten Lauber, Claus Belka, Nikko Brix, T. Seiwert

Publikováno v: Internist 61, 682-689 (2020)

HintergrundDas Therapieportfolio für rekurrente und/oder metastasierte Kopf-Hals-Plattenepithelkarzinome („Head and neck squamous cell carcinoma“ [HNSCC]) hat sich mit der klinischen Implementierung der Immuntherapie erweitert: Die einzige molek

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f73b647c9e877c298fbc148e3c30266c
https://doi.org/10.1007/s00108-020-00816-x

Zobrazit plný text záznamu

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

Publikováno v: Annals of oncology

Background: Targeting the immune checkpoint pathway has demonstrated antitumor cytotoxicity in treatment-refractory head and neck squamous cell carcinoma (HNSC). To understand the molecular mechanisms underpinning its antitumor response, we character

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0622521a467347accb2c13edaf303d9e
https://doi.org/10.1093/annonc/mdy470

Zobrazit plný text záznamu

[Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression]

Autor: N, Brix, L, Dunn, T, Seiwert, C, Belka, K, Lauber

Publikováno v: Der Internist. 61(7)

The clinical implementation of immunotherapy has broadened the therapeutic options for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Until 2016, the only molecularly targeted therapy was epidermal growth factor receptor (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::74eaef436d7639f93a90679e78652c01
https://pubmed.ncbi.nlm.nih.gov/32462252

Zobrazit plný text záznamu

Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

Autor: Yuji Ikeda, Kazuma Kiyotani, Jae-Hyun Park, Makda Zewde, Arun Khattri, Aiman Fatima, Nicole A. Cipriani, Mark W. Lingen, Everett E. Vokes, Ryan J. Brisson, Riyue Bao, Vassiliki Saloura, Theodore Vougiouklakis, T. Seiwert, Yusuke Nakamura

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 23(16)

Purpose: Squamous cell carcinoma of the head and neck (SCCHN) is a lethal cancer with a suboptimal 5-year overall survival of approximately 50% with surgery and/or definitive chemoradiotherapy. Novel treatments are thus urgently awaited. Immunotherap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a303c5ad3b7d9106d2d70e9ac438d2
https://pubmed.ncbi.nlm.nih.gov/28442504

Zobrazit plný text záznamu

Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data

Autor: Caroline Even, Roger B. Cohen, Esma Saada-Bouzid, J. Fayette, T. Seiwert, Dimitrios Colevas, Marshall R. Posner, P. Andre, F. Calmels, Sébastien Salas, A. Boyer-Chammard, G. Lefebvre, R. Zerbib, Jessica Bauman

Publikováno v: Annals of Oncology. 30:v460

Background Monalizumab is a first in class immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A), which is expressed as a heterodimer with CD94 on subsets of Natural Killer (NK), γδ T and tumor-infiltrating CD8+ T cells (Andre et al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::78ad9c45eb004ffea8cdf560b4219d2b
https://doi.org/10.1093/annonc/mdz252.026

Zobrazit plný text záznamu

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers

Autor: Everett E. Vokes, Joseph K. Salama, Daniel J. Haraf, Kerstin M. Stenson, M. E. Witt, T. Seiwert, R. Williams, R. Kunnavakkam, Elizabeth A. Blair, Ezra E.W. Cohen

Publikováno v: Annals of Oncology. 22:2304-2309

Introduction We conducted a randomized phase II study to evaluate the impact of adding bevacizumab (B) to 5-fluorouracil (5-FU), hydroxyurea (HU), and radiotherapy (FHX) for intermediate-stage and select T4 head and neck squamous cell cancers (HNSCC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ecbace8e7203e133064b9ac02ae785
https://doi.org/10.1093/annonc/mdq736

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání